Coya Therapeutics has launched a Phase 2 clinical trial of COYA 302 — an experimental therapy combining the signaling molecule IL-2 with CTLA4-Ig, also known as abatacept — to evaluate whether its use can slow disease progression in adults with amyotrophic lateral sclerosis (ALS) over a six-month period.

In adults with amyotrophic lateral sclerosis (ALS) who have slower disease progression, the stem cell therapy Neuronata-R (lenzumestrocel) — conditionally approved in South Korea for treating ALS — was found to help preserve daily function and breathing capacity, while also reducing signs of nerve damage and inflammation. That’s according to…

The UCLA ALS Clinic and Research Center has been officially designated a Certified Treatment Center of Excellence for people in the U.S. with amyotrophic lateral sclerosis (ALS) — making it the 100th center nationwide to receive such recognition. This designation, awarded by the ALS Association, means the…

Nonprofit I AM ALS has teamed up with actor Eric Dane to launch Push for Progress, a three-year campaign focused on accelerating research on amyotrophic lateral sclerosis (ALS), expanding access to treatments, and securing $1 billion in federal funding. Dane, best known for his roles in “Grey’s…

Cooler-than-average temperatures these last few weeks are turning our maple trees red, reminding me that winter is just around the corner. Due to caring for my husband, Todd, who has ALS, I don’t often get out to see the best of Michigan’s Upper Peninsula — such as the shores…

Come on, do we really need another reminder to practice self-care? I think we do. I know I need it, especially because I have ALS and am living in a world that’s barreling down a bumpy track. The type of self-care I’m currently focusing on isn’t a self-indulgent three-day vacation,…

Long-read DNA sequencing is a more accurate method than short-read sequencing for detecting certain defects in genes associated with an increased risk of sporadic amyotrophic lateral sclerosis (ALS), a new study suggests. A relatively new technique, long-read sequencing can capture data on thousands to hundreds of thousands of nucleotides,…

The investigational antisense oligonucleotide (ASO) therapy BIIB078 may have failed in amyotrophic lateral sclerosis (ALS) clinical trials because it wasn’t adequately reversing key disease processes in the brain and spinal cord. Analyses of body fluids and tissue from participants showed that, while BIIB078 reached key tissues, it couldn’t entirely…